Story perspectives

U.S. Diabetes Market Set to Surge by 2034

9/16/2025

25 3

Summary

Story summary

The Type 1 Diabetes market is expected to grow significantly by 2034, with the U.S. holding 89% of the market share.
Major companies like Eli Lilly, Sanofi, Novo Nordisk, and Provention Bio are developing innovative therapies, including TZIELD and weekly insulins.
The market is shifting from traditional insulin therapies to disease-modifying treatments and advanced delivery systems.
Regulatory milestones include FDA approvals for TZIELD and new therapies such as CNP-103 and Merilog.
The U.S. has 56% of diagnosed cases, with Germany leading in the EU, and the patient population is increasing due to better diagnostics and awareness, especially among older adults.

1 of 1

Story summary

The Type 1 Diabetes market is expected to grow significantly by 2034, with the U.S. holding 89% of the market share.
Major companies like Eli Lilly, Sanofi, Novo Nordisk, and Provention Bio are developing innovative therapies, including TZIELD and weekly insulins.
The market is shifting from traditional insulin therapies to disease-modifying treatments and advanced delivery systems.
Regulatory milestones include FDA approvals for TZIELD and new therapies such as CNP-103 and Merilog.
The U.S. has 56% of diagnosed cases, with Germany leading in the EU, and the patient population is increasing due to better diagnostics and awareness, especially among older adults.